Strategic IP for Oligonucleotide Therapeutics: Maximizing Innovation Value

Jean Ge focuses on providing strategic intellectual property counsel to a wide range of clients in the biotechnology and pharmaceutical spaces. Jean represents clients ranging from venture-backed start-up companies and multinational pharmaceutical companies to financial institutions, such as private equity and venture capital firms, to research institutions. With nearly 10 years of research experience in the RNA field prior to joining Wolf Greenfield, Jean has a deep appreciation of the opportunities and challenges in RNA research and drug development and is uniquely positioned to facilitate the commercialization of oligonucleotide therapeutics from technical, legal, regulatory, and business perspectives.